10-Q: Centene Reports Q2 Loss Amid Rising Medical Costs and Marketplace Risk Adjustment Headwinds

Centene Corporation reported a significant net loss in the second quarter of 2025, primarily driven by increased medical costs and a reduction in Marketplace risk adjustment revenue estimates, despite strong revenue growth.

Summary

• Total revenues increased by 22% to $48.7 billion for the three months ended June 30, 2025, compared to $39.8 billion in the prior year period.
• Premium and service revenues grew 18% to $42.5 billion for the three months ended June 30, 2025.
• GAAP net loss attributable to Centene Corporation was $253 million, or $(0.51) per diluted share, for Q2 2025, a significant decline from net earnings of $1,146 million, or $2.16 per diluted share, in Q2 2024.
• Adjusted net loss was $79 million, or $(0.16) per diluted share, for Q2 2025, compared to adjusted net earnings of $1,283 million, or $2.42 per diluted share, in Q2 2024.
• The Health Benefits Ratio (HBR) increased to 93.0% in Q2 2025 from 87.6% in Q2 2024, primarily due to reduced Marketplace risk adjustment revenue estimates and higher medical costs.
• Selling, General and Administrative (SG&A) expense ratio improved to 7.1% in Q2 2025 from 8.0% in Q2 2024, driven by leveraging expenses over higher revenues.
• Managed care membership decreased by 473 thousand members, or 2%, year-over-year to 28.0 million as of June 30, 2025.
• Medicaid membership declined due to redeterminations, while Marketplace membership increased 33% year-over-year.
• Medicare Prescription Drug Plan (PDP) membership increased 19% year-over-year, but Medicare Advantage membership declined 10%.
• An intangible asset impairment charge of $55 million was recorded in Q2 2025 related to the wind-down of certain contracts in the Other segment.
• Operating cash flows for the six months ended June 30, 2025, increased to $3.3 billion from $1.7 billion in the comparable 2024 period.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant net loss, a substantial increase in the Health Benefits Ratio driven by higher medical costs and adverse risk adjustment, and a worsening outlook for key segments like Medicare Advantage and Marketplace due to regulatory changes and increased morbidity. While revenue growth and SG&A efficiency are positive, they are overshadowed by the profitability challenges and the potential for future impairments and membership declines.

Positives

• Total revenues increased by 22% year-over-year to $48.7 billion for the three months ended June 30, 2025, demonstrating strong top-line growth.
• Premium and service revenues grew 18% year-over-year to $42.5 billion in Q2 2025.
• The SG&A expense ratio improved to 7.1% in Q2 2025 from 8.0% in Q2 2024, indicating improved operational efficiency and leveraging of expenses over higher revenues.
• Operating cash flows significantly increased to $3.3 billion for the six months ended June 30, 2025, compared to $1.7 billion in the prior year, driven by net earnings and improved pharmacy rebate remittance timing.
• Medicare Prescription Drug Plan (PDP) membership increased by 19% year-over-year to 7.8 million members, reflecting successful bid positioning.
• Marketplace membership grew by 33% year-over-year due to expanded geographic footprint and strong open enrollment results.
• The debt-to-capital ratio decreased to 39.0% at June 30, 2025, from 41.2% at December 31, 2024, indicating improved financial leverage.
• The company maintains a strong liquidity position with $1.1 billion in unregulated cash and investments and sufficient available cash and credit facilities to finance operations for at least 12 months.

Negatives

• GAAP net loss attributable to Centene Corporation was $253 million in Q2 2025, a substantial decline from net earnings of $1,146 million in Q2 2024.
• Adjusted net loss was $79 million in Q2 2025, a significant reversal from adjusted net earnings of $1,283 million in Q2 2024.
• The Health Benefits Ratio (HBR) increased to 93.0% in Q2 2025 from 87.6% in Q2 2024, primarily due to a reduction in the net 2025 Marketplace risk adjustment revenue transfer estimate and increased Marketplace medical costs.
• Higher medical costs in Medicaid were observed, driven by behavioral health, home health, and high-cost drugs.
• The 2025 Medicare Advantage premium deficiency reserve increased to $389 million in Q2 2025, up from $270 million in Q1 2025 and $92 million in December 2024, indicating worsening profitability expectations for this segment.
• Managed care membership decreased by 473 thousand members, or 2%, year-over-year, primarily due to Medicaid redeterminations.
• Medicare Advantage membership declined by 10% year-over-year.
• An intangible asset impairment charge of $55 million was recorded in Q2 2025 related to the wind-down of certain contracts in the Other segment.
• Investment and other income decreased by $92 million in Q2 2025 compared to Q2 2024, primarily due to lower interest rates and average investment balances.

Risks

• Inability to accurately estimate and price medical expenses or effectively manage medical costs, including fluctuations due to consumer/provider behaviors, inflation, and new high-cost pharmaceuticals.
• Rate cuts, insufficient rate changes, or payment reductions/delays by government payors affecting government businesses.
• Changes in federal or state laws or regulations, including those related to the ACA, Inflation Reduction Act (IRA), and the One Big Beautiful Bill Act (OBBBA), which could reduce membership or profitability.
• Unanticipated increased healthcare costs due to changes in consumer and provider behaviors, inflation, and tariffs.
• Inability to maintain or achieve improvement in CMS Star ratings and other quality scores, impacting revenue and future growth.
• Competition for providers, broker distribution networks, contract reprocurements, and organic growth.
• Inability to adequately anticipate demand and timely provide operational resources to maintain service level requirements.
• Disruption, unexpected costs, or similar risks from business transactions, including acquisitions, divestitures, and changes in third-party vendor relationships.
• Impairments to real estate, investments, goodwill, and intangible assets, with a quantitative impairment analysis planned post-June 30, 2025, due to market conditions.
• Changes in senior management, loss of key personnel, or inability to attract/retain skilled personnel.
• Membership and revenue declines or unexpected trends, particularly from Medicaid redeterminations and changes in Marketplace eligibility.
• Changes in healthcare practices, new technologies, and advances in medicine.
• Risks associated with the ethical use of artificial intelligence and machine learning.
• Changes in macroeconomic conditions, including inflation, interest rates, and volatility in financial markets.
• Negative public perception of the company and the managed care industry.
• Uncertainty concerning government shutdowns, debt ceilings, or funding, which could delay payments.
• Tax matters and potential changes in tax laws.
• Disasters, climate-related incidents, acts of war or aggression, or major epidemics.
• Changes in expected contract start dates and terms, and delays in regulatory approval of contracts.
• Expiration, suspension, or termination of contracts with federal or state governments.
• Difficulty predicting the timing or outcome of legal or regulatory audits, investigations, or proceedings, including the federal securities class action.
• Challenges to contract awards, such as ongoing protests in Georgia and Texas Medicaid procurements.
• Cyber-attacks or other data security incidents, or failure to comply with privacy, data, or security laws.
• Exertion of management's time and resources, and other expenses incurred in complying with contract terms and regulatory undertakings.
• Losses in the investment portfolio due to interest rate risk or credit quality changes.
• Restrictions and limitations in connection with indebtedness, and potential downgrade of corporate credit ratings.
• Availability of debt and equity financing on favorable terms.
• Delays in payments from CMS for Part D risk-sharing programs (expected 12-13 months after plan year closes) could materially adversely affect cash flows.
• Increased bad debt exposure and estimation uncertainty from the Medicare Prescription Payment Plan (M3P) due to deferred out-of-pocket payments.

Future Outlook

The company anticipates continued challenges from an accelerated increase in medical cost trends, driven by increased demand, expanded access, and high-cost pharmaceuticals. The combined effect of the expiration of enhanced Advance Premium Tax Credits (APTCs), the Marketplace Integrity & Affordability Final Rule, and the One Big Beautiful Bill Act (OBBBA) is expected to reduce 2026 Marketplace membership and increase the overall morbidity of the Marketplace population. The company has commenced refiling 2026 policy year rates to reflect a higher projected baseline of Marketplace morbidity and expects to take corrective pricing actions for 2026 in states representing a substantial majority of its Marketplace membership. The company expects a net contribution of approximately $300 million to its insurance subsidiaries and approximately $350 million in additional capital expenditures for the remainder of 2025. A quantitative impairment analysis is planned post-June 30, 2025, which may result in a goodwill or intangible asset impairment charge due to market conditions, including the OBBBA. The company believes its available cash, investments, and credit facility will be sufficient to finance general operations and capital expenditures for at least 12 months.

Management Comments

• We are currently experiencing an accelerated increase in medical cost trend, driven by increasing medical demand, expanded access to care facilitated by program changes at the state level, and the rapid release and availability of new, high-cost pharmaceuticals.
• We continue to work with our state partners to establish Medicaid premium rates that appropriately match the acuity of the population as well as reflect the most recent medical cost trend.
• We are committed to ensuring that the affordability of healthcare is maintained for our government partners and members and continue to address the cost trend through the implementation of new clinical initiatives and care management plans, thoughtful network design, and ongoing rigor to combat fraud, waste and abuse.
• We continue to believe we have both the capacity and capability to successfully navigate industry changes to the benefit of our members, customers, providers, and shareholders.

Industry Context

The managed care industry is facing significant headwinds from rising medical costs, particularly in behavioral health, home health, and high-cost drugs. Regulatory changes, such as the expiration of enhanced APTCs, the Marketplace Integrity & Affordability Final Rule, and the newly passed One Big Beautiful Bill Act (OBBBA), are creating substantial uncertainty. These changes are expected to reduce Marketplace membership and increase the morbidity of the remaining population, impacting profitability. Medicaid redeterminations continue to reduce membership and increase the acuity of the remaining Medicaid population. The Inflation Reduction Act (IRA) has significantly altered Medicare Part D, shifting cost-sharing responsibilities and increasing risk exposure for plans, although the Part D Premium Stabilization Demonstration program aims to mitigate some of these impacts. The industry is adapting to these legislative and cost pressures, with companies like Centene focusing on rate adjustments, clinical initiatives, and network design to manage profitability.

Comparison to Industry Standards

• No specific comparable companies, projects, or results were mentioned in the filing for direct comparison to industry standards.

Corporate Governance

Legal Proceedings

• A putative federal securities class action, Brock Lunstrom v. Centene Corp., et al., was filed on July 9, 2025, in the U.S. District Court for the Southern District of New York, alleging false and misleading statements regarding the company's 2025 earnings guidance. The company denies wrongdoing and is vigorously defending itself, but an adverse outcome could have a material adverse impact on financial position and results of operations.

Stakeholder Impact

• Shareholders: Experienced a significant net loss and diluted EPS loss, impacting shareholder value. The company continues its stock repurchase program, with $1.8 billion remaining, which could provide some support.
• Members: Face potential changes in eligibility and affordability of health insurance due to regulatory changes like the OBBBA and the expiration of enhanced APTCs, potentially leading to reduced coverage or increased costs for some.
• Employees: No direct impact mentioned, but overall company performance and strategic shifts could indirectly affect employment stability or compensation.
• Providers: May experience changes in reimbursement models and payment rates due to state policy decisions and federal funding adjustments, potentially impacting their operations and relationships with the company.
• Government Payors: The company continues to work with state and federal partners on rate adjustments and program design, indicating ongoing collaboration and negotiation regarding funding and policy implementation.
• Creditors: The company maintains compliance with debt covenants and has a strong liquidity position, suggesting stability for creditors, though potential future capital raises could alter the debt structure.

Next Steps

• Continue working with state partners to establish Medicaid premium rates that appropriately match the acuity of the population post-redeterminations.
• Refile 2026 policy year rates for Marketplace products to reflect a higher projected baseline of morbidity and take corrective pricing actions in states representing a substantial majority of Marketplace membership.
• Implement new clinical initiatives and care management plans, thoughtful network design, and ongoing rigor to combat fraud, waste and abuse to address medical cost trends.
• Perform a quantitative impairment analysis to determine whether goodwill, intangibles, or other assets are impaired, which may result in a future impairment charge.
• Continue to advocate for legislation and regulations aimed at leveraging Medicaid and the Health Insurance Marketplace to maintain health insurance coverage and affordability for consumers.
• Navigate evolving regulations related to dual-eligible beneficiaries receiving integrated care through Medicare Advantage Dual Eligible Special Needs Plans (D-SNPs) beginning in 2027 and 2030.
• Monitor and litigate ongoing Medicaid procurement protests in Georgia and Texas.

Key Dates

Recommendation

The filing reveals a substantial GAAP and adjusted net loss for Q2 2025, a dramatic reversal from prior year profitability. This is driven by a significant increase in the Health Benefits Ratio (HBR) due to higher medical costs and a material negative adjustment to Marketplace risk adjustment revenue. Furthermore, the outlook is clouded by adverse regulatory changes (OBBBA, APTC expiration) expected to reduce membership and increase morbidity in key segments, and the company anticipates a potential goodwill/intangible impairment. While revenue growth and SG&A efficiency are positive, they are insufficient to offset the core profitability challenges and the negative forward-looking indicators. The combination of current losses, rising costs, and a challenging regulatory environment suggests significant downside risk, warranting a 'strong sell' recommendation for a seasoned investor.

Keywords

Healthcare, Managed Care, Medicaid, Medicare, Health Insurance Marketplace, SEC Filing, Financial Results, 10-Q, Medical Costs, Risk Adjustment, Premium Deficiency, Membership, Regulatory Changes, Inflation Reduction Act, OBBBA